Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-62.26	-61.43	-36.31	-27.71	-9.19
Depreciation & Amortization	0.67	0.5	0.37	0.34	0.15
Stock-Based Compensation	7.73	7.63	2.89	1.76	0.23
Other Adjustments	2.89	1.81	0.29	0.63	0.13
Change in Receivables	-	-	-	1.16	-1.29
Changes in Accounts Payable	-0.24	0.52	-0.63	1.01	0.46
Changes in Accrued Expenses	-1.62	4.01	-0.36	2.47	0.64
Changes in Other Operating Activities	-0.11	-0.46	0.29	-0.06	-0.38
Operating Cash Flow	-53.27	-47.42	-33.45	-20.39	-9.26
Capital Expenditures	-0.53	-2.08	-0.47	-0.73	-0.68
Investing Cash Flow	-0.53	-2.08	-0.47	-0.73	-0.68
Long-Term Debt Issued	29.53	-	-	9.83	-
Long-Term Debt Repaid	-15.32	-	-	-	-
Net Long-Term Debt Issued (Repaid)	14.21	-	-	9.83	-
Issuance of Common Stock	0.5	137.77	0.18	0.04	0.01
Net Common Stock Issued (Repurchased)	0.5	137.77	0.18	0.04	0.01
Issuance of Preferred Stock	-	-	70	34.26	31.89
Net Preferred Stock Issued (Repurchased)	-	-	70	34.26	31.89
Other Financing Activities	0.63	-2.08	-2.05	-0.34	-0.21
Financing Cash Flow	9.94	135.69	68.13	43.79	31.69
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.02	-0.01	-0.01	-0.02	-0.05
Net Cash Flow	-43.89	86.18	34.2	22.64	21.7
Free Cash Flow	-53.8	-49.5	-33.92	-21.13	-9.94
Free Cash Flow Per Share	-1.99	-2.01	-9.09	-6.13	-
Levered Free Cash Flow	-49.87	-58.94	-37.1	-14.85	-9.01
Unlevered Free Cash Flow	-68.13	-66.12	-38.6	-26.16	-12.09

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q